Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 7Pancreatic Neoplasms 6Brain Neoplasms 6Neoplasms 5Glioma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Liver Neoplasms 2Glioblastoma 2Disease 2Central Nervous System Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1Soft Tissue Neoplasms 1Recurrence 1Rectal Neoplasms 1Penile Neoplasms 1Pediatric Brain Tumor 1Pancreatic Cyst 1Osteosarcoma 1Nervous System Diseases 1Muscle Weakness 1Metabolic Diseases 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1

Interventions

Cisplatin 4Etoposide 3atezolizumab 2Drug Therapy 2Carboplatin 2tivozanib 1repotrectinib 1lutetium Lu 177 dotatate 1durvalumab 1dostarlimab 1belinostat 1Somatostatin 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Magnetic Resonance Imaging 1Ipilimumab 1FOLFOXIRI protocol 1EC regimen 1DLL3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Neuroendocrine × Magnetic Resonance Imaging × Clear all
NCT07458906 2026-03-09

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

The First Affiliated Hospital of Xiamen University

Phase NA Recruiting
60 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡